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Abstract
Background: Allergic Rhinitis is a common Ear, Nose and Throat disorder. Asthma and Allergic Rhinitis are diseases
with similar underlying mechanism and pathogenesis. The aim of this survey was to highlight current treatment
trends for Allergic Rhinitis and Asthma.
Method: A questionnaire was emailed to all registered consultant members of the British Association of
Otorhinolaryngologists - Head and Neck Surgeons regarding the management of patients with Allergic Rhinitis and
related disorders.
Results: Survey response rate was 56%. The results indicate a various approach in the investigation and
management of Allergic Rhinitis compatible with recommendations from the Allergic Rhinitis and Its Impact on
Asthma guidelines in collaboration with the World Health Organisation.
Conclusion: A combined management approach for patients with Allergic Rhinitis and concomitant Asthma may
reduce medical treatment costs for these conditions and improve symptom control and quality of life.
Keywords: Allergic Rhinitis Asthma, Survey, Questionnaire, Atopy
Background
The definition of Allergic Rhinitis (AR) was formulated
by Hansel in 1929 [1]. It is a symptomatic nasal disorder
caused by allergen exposure through an IgE-mediated
immune response against allergens. AR can be subdi-
vided into intermittent (symptoms <4 days per week or
for <4 weeks) and persistent disease (symptoms >4 days
per week or for >4 weeks) and is further characterized
according to severity as mild or moderate/severe [2].
The nasal passage and paranasal sinuses are an inte-
gral part of the respiratory tract and patients may have
rhinitis without sinusitis, but not sinusitis without rhini-
tis, hence the term rhinitis has been replaced in modern
ENT literature by the more accurate term rhinosinusitis
[3]. AR and Asthma are linked epidemiologically, patho-
logically, physiologically and therapeutically and can be
considered as a manifestation of a single inflammatory
airway syndrome [4]. Most patients with Asthma have
rhinitis suggesting the concept of “one airway, one dis-
ease” [5]. AR is more prevalent than Asthma and a
European population study was reported to have an AR
prevalence rate of 25% [6]. AR usually precedes Asthma
and can be considered as risk factor for the develop-
ment of Asthma. Rhinitis exists in up to 80% of Asthma
patients and frequently exacerbates Asthma and
increases the risk of Asthma attacks, but the prevalence
of Asthma in patients with rhinitis varies from 10 - 40%
[7]. AR and Asthma are chronic respiratory diseases
that cause major disability worldwide including impaired
sleep, school, work and quality of life and are associated
with substantial economic costs [8].
The aetiology of AR is multi-factorial and the diagnos-
tic and therapeutic choices remain diverse. The aim of
this questionnaire survey was to highlight the treatment
trends in the management of AR amongst UK-based
otolaryngologists.
Methods
A questionnaire (Appendix 1) was emailed via ENT UK
to the email addresses of all registered consultant mem-
bers of the British Association of Otorhinolaryngologists
- Head and Neck Surgeons (BAO-HNS). Survey recipi-
ents were asked 1) about their familiarity with the
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guidelines in collaboration with the World Health Orga-
nisation (WHO), 2) about the type of investigations,
treatment regimes and follow-up arrangements for AR
patients and 3) about whether they give to patients
advice leaflets on life style changes including education
and allergen avoidance. All participants had the oppor-
tunity to answer anonymously.
Results
A total of 551 questionnaires were emailed. There were
309 replies (56% response rate). All consultants were
familiar with the association between AR and Asthma
but only 63% of the respondents were familiar with the
ARIA guidelines. Seventy seven (25%) of otolaryngolo-
gists managed AR patients of which a 20 - 30% propor-
tion had associated symptoms or a diagnosis of Asthma
(Figure 1).
The commonest investigation requested was skin prick
testing (81% of respondents). Only nine consultants (3%)
arranged pulmonary spirometry (Figure 2).
Fifty six per cent of otolaryngologists preferred the
management pathway of starting treatment and then
discharging AR patients to General Practitioners (GPs)
for further follow-up. However three (1%) consultants
managed and subsequently referred AR patients to a
respiratory physician (Figure 3).
In total two hundred and forty (78%) of otolaryngolo-
gists provided patient leaflets on life-style changes
including education and practical tips on allergens
avoidance. (Figure 4)
Discussion
AR is a multi-factorial disease with a worldwide dis-
abling effect on all individuals irrespective of age and
ethnic background. In 2001 the ARIA in collaboration
with the WHO workshop published guidelines for
healthcare professionals in order to highlight the latest
updates on the aetiology of AR emphasizing the
association between AR and Asthma and proposing a
management algorithm [2]. In 2008 a further update
incorporated evidence based practice and the Grading of
Recommendations Assessment, Development and Eva-
luation (GRADE) Working Group methodology with a
focus on the prevention of allergic and chronic respira-
tory diseases [9].
Risk factors for AR include a combination of environ-
mental and genetic interactions [10]. The diagnosis of
AR is based upon a thorough history of allergic symp-
toms and diagnostic investigations. The European Acad-
emy of Allergiology and Clinical Immunology, the US
Joint Council of Allergy and Asthma and the WHO
recommend the use of skin prick testing for AR, which
is preferred by the majority of UK otolaryngologists
(81%) [11].
An overwhelming 99% of UK ENT consultants use
intra-nasal steroids to treat AR. This trend is supported
by several studies demonstrating that intra-nasal steroids
Figure 1 Proportion of Allergic Rhinitis patients that have
Asthma.
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treatment for AR [12,13].
Allergen specific immunotherapy for AR was first
described in 1911 by Noon and involves the administra-
tion of a gradually increasing quantity of an allergen
extract [14]. Patients are selected with demonstrated
specific IgE antibodies to known allergens. In the USA
the subcutaneous route is the only licensed route of
administration. Interestingly 15% of UK otolaryngolo-
gists used sublingual and 5% used subcutaneous forms
of immunotherapy. There is increasing evidence sup-
porting the use of allergen immunotherapy in AR.
Unlike pharmacotherapy, the clinical benefits are likely
to be sustained for many years after discontinuation of
treatment [15]. Wilson et al i nac o c h r a n er e v i e w
s h o w e ds u b l i n g u a li m m u n o t h e r a p yt ob eas a f ea n d
effective option in managing AR [16]. Furthermore, Cal-
deron et al in a recently published meta-analysis advo-
cate the use of allergen injection immunotherapy as an
effective treatment with a low risk of adverse effects in
the management of AR [17]. However, further studies
are required to evaluate significant differences between
these two routes. Allergen specific immunotherapy is
not recommended in patients with severe or uncon-
trolled Asthma because of risk of adverse bronchial
reactions [18].
The importance of educating patients or carers with
advice leaflets with information regarding AR including
allergen avoidance cannot be over emphasised and was
actively supported by 78% of responders of this survey.
This enables individuals to be actively involved in the
management of their disease resulting in an overall
improvement in patient satisfaction, treatment compli-
ance and outcomes [19]. Such practice is endorsed by
the General Medical Council (GMC) through its gui-
dance on good medical practice for doctors [20].
Interestingly, only 3% of otolaryngologists arranged
pulmonary spirometry and 1% of all respondents
referred AR patients to a respiratory physician for man-
agement of any associated lower respiratory tract pathol-
ogy. Several studies though have demonstrated that AR
patients with no underlying Asthma do have impaired
pulmonary function and reversible airway obstruction
[21,22]. In addition, studies have revealed that AR is
linked to an increased use of Asthma related medical
services and that the treatment of either AR or that of
Asthma can alleviate the symptoms of the other and
hence reduce the number of days off school and work
and costs of utilising medical services loss of employ-
ment productivity [23,24]. Furthermore, greater aware-
ness of the economic burden of AR would assist
healthcare providers in establishing priorities for the
allocation of their limited resources and ultimately
ensure cost and clinical effective outcomes [25].
Conclusion
This survey demonstrates as expected a diverse approach
to the management of Allergic Rhinitis. An interesting
finding of the survey is that despite good evidence on the
relationship between Asthma and AR, most otolaryngolo-
gists often do no think “outside the specialty”, for example
they would rarely use spirometry as a diagnostic aid.
A combined treatment strategy of allergen avoidance,
pharmacotherapy, immunotherapy and education applied to
patients with AR and concomitant Asthma as recom-
mended by the ARIA guidelines may reduce medical treat-
ment costs and improve symptom control and quality of life.
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APPENDIX 1: Allergic Rhinitis E-mail
Questionnaire
Dear colleague,
Pease could you complete this survey with your
responses and return it by clicking the SUBMIT button
below. We thank you for your valuable time in complet-
ing this survey.
1. Are you familiar with the association between
Allergic Rhinitis and Asthma?
Figure 4 Treatment for Allergic Rhinitis.
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￿ No
2. Are you familiar with the Allergic Rhinitis and its
impact on Asthma (ARIA) guidelines in collabora-
tion with the World Health Organisation?
￿ Yes
￿ No
3. What proportion of your patients with Allergic
Rhinitis have got symptoms or diagnosis of Asthma?
￿ <10%
￿ 10 - 20%
￿ 20 - 30%
￿ 30 - 40%
￿ 40 - 50%
￿ >50%
4. If you suspect Allergic Rhinitis what investigations
would you consider (you may tick one, or more of
the following)?
￿ None
￿ Skin prick test to known allergens
￿ Serology tests e.g. RAST, IgE
￿ Peak flow meter (air flow litres/minute)
￿ Pulmonary spirometry
5. If you suspect Allergic Rhinitis in a patient which
of the following management plans would you
consider?
￿ Start treatment and review
￿ Start treatment and discharge patient to GP for
follow-up
￿ Start treatment and refer to a Respiratory
Physician
6. If you suspect Allergic Rhinitis which of the fol-
lowing would you use for treatment (you may tick
one, or more of the following)?
￿ Antihistamine - oral
￿ Antihistamine - intra-nasal
￿ Steroid - intra-nasal
￿ Steroid - intra-bronchial
￿ Steroid - oral
￿ Decongestant - oral
￿ Decongestant - intra-nasal
￿ Anti-cholinergic (Ipatropium Bromide)
￿ Anti-leukotriene
￿ Specific Immunotherapy - sublingual
￿ Specific Immunotherapy - subcutaneous
7. How long do you prescribe nasal sprays for
￿ 3 months
￿ 6 months
￿ >6 months
8. What is the frequency of nasal spray administra-
tion do you prescribe (you may tick one, or more
from the following)?
￿ Two puffs once a day
￿ Two puffs twice a day
￿ Other (please specify)
9. Do you provide leaflets for patients about life-style
changes including education and avoidance of aller-
gen(s)?
￿ Yes
￿ No
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